Preclinical development of a prenyltransferase inhibitor to treat inflammatory neuropathy - inflammatory neuropathies are one of the largest and least understood spectrums of neurologic disorders
Active Grant Awarded
- Award ID
- R61NS146354
- Recipient
-
Loyola University Of Chicago UEI RFRPFMNR8LA5
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $342,420
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 13% complete
- Place of performance
- Maywood, IL 60153, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded Loyola University of Chicago's Health Sciences Campus division a grant totaling $342,420 on August 21, 2026, under Assistance Listing 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders. The award funds preclinical development of FGTI-2734, a protein prenyltransferase inhibitor, as an alternative to statins for treating the acute inflammatory demyelinating polyneuropathy (AIDP) variant of Guillain-Barré syndrome. Co-investigator Dr. Sebti developed FGTI-2734.
The R61 phase assesses dose-dependent effects on chemokine release from rat and human blood nerve barrier endothelial cells. It also investigates acute and chronic pharmacokinetics, pharmacodynamics, and toxicity in naive rats and in rats with experimental autoimmune neuritis (EAN), and evaluates clinical protection in the EAN rats. The R33 phase evaluates clinical and functional improvement. The application is structured as an R61/R33 IGNITE award.
The obligated amount is $342,420, with a period of performance running from August 21, 2026 to July 31, 2028. Work is performed in Maywood, Illinois 60153. The assistance type is a grant.
Description
Among them is the acute inflammatory demyelinating polyneuropathy (AIDP) variant of guillain-barré syndrome, a disabling autoimmune disease that affects the peripheral nerves. Despite representing a major socioeconomic strain, treatment options available for patients suffering from AIDP remain palliative, non-specific, and ineffective. Statin treatment therapeutically attenuates the experimental autoimmune neuritis (EAN) RAT model of AIDP by limiting immune cell trafficking into nerves. While statins' widely observed beneficial pleiotropic effects support this finding, their association with muscle toxicity and potential to disrupt cholesterol homeostasis in nerve myelin preclude further clinical translation. We seek to identify alternatives to statins that may achieve similar anti- inflammatory effects. Our in vitro data suggest that statins attenuate gtpase-dependent release of inflammatory chemokines from blood nerve barrier (BNB) endothelial cells. This effect is mimicked by protein prenyltransferase inhibitors. CO-I on this application, DR. Sebti, has developed dozens of prenyltransferase inhibitors, including most recently fgti-2734. Preliminary data from our lab and others demonstrate that fgti-2734 exerts anti- inflammatory effects by several different mechanisms. This R61/R33 ignite application will investigate the potential of fgti-2734 as a novel therapeutic in the EAN model of AIDP. The R61 phase will 1) assess dose- dependent effects on chemokine release from RAT BNB endothelial cells and human endothelial cells, 2) investigate acute PK, PD, and toxicity in naïve rats and rats at EAN peak and 3) assess clinical protection, chronic PK, PD, and toxicity in rats with EAN. The R33 phase will 1) evaluate clinical and functional improvement and 2) assess nerve myelination and immune cell infiltration in EAN rats receiving a therapeutic course of fgti- 2734 or vehicle. The overall goal of this milestone-driven ignite proposal is to develop fgti-2734 as a therapy for AIDP.
Quick answers
Who received award R61NS146354?
R61NS146354 was awarded to Loyola University Of Chicago by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on August 21, 2026.
How much is award R61NS146354 worth?
$342,420 has been obligated on R61NS146354.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award